Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire PLC    SHP   JE00B2QKY057


Delayed Quote. Delayed  - 02/21 05:35:17 pm
4810.5 GBp   +0.20%
07:46a SHIRE : *hsbc raises shire price target to 4,550 (4,500) pence - 'ho..
02/20 British FTSE 100 decreases 0.34 pct on Thursday
02/20 SHIRE : Director/PDMR Shareholding
News SummaryMost relevantAll newsSector newsTweets 

Shire Plc. : Shire Buying Pervasis To Advance Regenerative Medicines Business

share with twitter share with LinkedIn share with facebook
share via e-mail
04/12/2012 | 05:49pm CET
  By Sten Stovall 

Shire PLC (SHP.LN) is buying the assets of U.S.-based Pervasis Therapeutics in a deal that brings a new technology aimed at improving blood vessel repair for dialysis patients to the U.K. drug maker's regenerative medicine business.

A specialist in hyperactivity and rare genetic diseases, Shire is also expanding its activities in regenerative medicine to find products for replacing human cells, tissues or organs to restore or establish normal function.

Toward that end, Shire on Thursday said it will pay Pervasis an undisclosed upfront payment, plus milestones if Pervasis' lead product, a cell-based therapy called Vascugel, hits certain clinical, regulatory and sales targets. No financial terms were disclosed.

Pervasis, based in Cambridge, Massachusetts, is developing acute vascular repair technologies for patients with end-stage renal disease, or ESRD, which is an advanced and irreversible kidney disease. There are around 600,000 people in the U.S. and more than 250,000 in the EU currently being treated for ESRD.

Shire said its deal with Pervasis will make a strong strategic fit with its existing Dermagraft treatment for diabetic foot ulcers.

Diabetes is the chief cause of ESRD, while diabetic patients on dialysis have a greater risk of developing a diabetic foot ulcer than diabetics not receiving dialysis treatment.

Shire's head of regenerative medicine, Kevin Rakin, said that "this acquisition marks a very important step for Shire in building a regenerative medicine business focused on tissue repair and regeneration."

He told Dow Jones Newswires that Vascugel is currently in mid-stage clinical trials and will be progressing to late-stage Phase III testing soon. Vascugel has received Orphan Product designation from the U.S. Food and Drug Administration and from the European Medical Agency. If all goes well, marketing authorization could be sought for Vascugel by 2017, Rakin said.

Pervasis will give Shire a new cell-based technology platform called endothelial cell technology that has global potential. "We are looking at generating other products out of this platform," Rakin said.

"We're building our regenerative medicine activities because we believe it's one of the next big areas of medicine and so this adds to the Dermagraft purchase and we're building up our pipeline now. We're committed to doing this."

- By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIRE PLC
07:46a SHIRE : *hsbc raises shire price target to 4,550 (4,500) pence - 'hold'
02/20 British FTSE 100 decreases 0.34 pct on Thursday
02/20 SHIRE : Director/PDMR Shareholding
02/20 SHIRE PLC (NASDAQ : SHPG) Files An 8-K Other Events
02/17DJSHIRE : Files 8K - Other Events
02/17 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
02/16 SHIRE : Pharma group Shire produces top-of-the-range earnings
02/16DJSHIRE : Profit Soars on New Baxalta Revenue, Lifting Shares --Update
02/16 SHIRE : Directorate change
02/16 SHIRE : beats Street 4Q forecasts
More news
Sector news : Pharmaceuticals - NEC
02:48pDJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
01:24pDJBAYER : Proposes Higher Dividend for 2016
11:58a Why TEVA Stock Has Been on a Prolonged Dive
08:48aDJBAYER : Investors Upbeat on Takeover -- WSJ
03:32a Collapse of Kraft-Unilever tie-up extends run of failed mega-deals
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/20 Tracking John Paulson's Paulson & Company Portfolio - Q4 2016 Update
02/20 Why Shire's 2017 Guidance Is Encouraging And Should Reassure Investors
02/16 Shire Plc (SHPG) Q4 2016 Results - Earnings Call Transcript
02/16 Shire PLC 2016 Q4 - Results - Earnings Call Slides
02/16 Shire PLC beats by $0.13, beats on revenue
Financials ($)
Sales 2017 15 208 M
EBIT 2017 5 922 M
Net income 2017 3 050 M
Debt 2017 18 404 M
Yield 2017 0,61%
P/E ratio 2017 16,66
P/E ratio 2018 13,01
EV / Sales 2017 4,75x
EV / Sales 2018 4,15x
Capitalization 53 906 M
More Financials
Duration : Period :
Shire PLC Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Full-screen chart
Technical analysis trends SHIRE PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 73,8 $
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
David R. Ginsburg Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE PLC1.69%53 906
JOHNSON & JOHNSON3.17%323 362
ROCHE HOLDING LTD.4.69%209 882
PFIZER INC.3.51%204 018
NOVARTIS AG3.91%200 997
MERCK & CO., INC.11.08%180 289
More Results